glp-1 효능 제2형 당뇨병 및 비만에 대한 의약품의 효능과 안전성** 제2형 당뇨병과 비만을 위한 glucagon-like peptide 1 receptor agonists (GLP-1RA)의 개발 이후 일부 환자 집단에서 GLP-1RA의 심혈관계 이점을 입증하는 연구 결과들이 이어졌습니다. 또한 바이킹, GLP-1·GIP작용제 비만 1상서 효능

At a first pass, these data suggest the possibility that it was pancreatic glucagon rather than pancreatic GLP-1 that was responsible for the ability of Ex9 to impair glucose tolerance in the previous study (27)

GIP receptor research: GIPR signaling is commonly studied in incretin biology, cellular communication, and metabolic model systems

10.1161/CIRCRESAHA.116.308398 19

Diabetes Nutr Metab 17(6):336342 American Diabetes Association (2019) Standards of care in diabetes

Efficacy and Safety of the Combination or Monotherapy with GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: An Update Systematic Review and Meta-Analysis

8.3 Clinical decision matrix: stratification by metabolic phenotype and reproductive timeline 8.3.1 Dimensions Vertical Axis: High Risk: BMI 30 kg/m 2 comorbid with IR, MASLD, impaired glucose tolerance (IGT), or a significant family history of cardiovascular disease